KNSA (Kiniksa Pharmaceuticals, Ltd.) רווח נקי
The growth of Kiniksa Pharmaceuticals (KNSA) is based on the development of therapies for rare autoimmune pathologies and the diversification of its R&D portfolio. The company's net income clearly confirms this success, while the 0.11 metric characterizes this valuation parameter. Monopoly status is ensured by patent protection of antibodies, while a high-demand drug for the treatment of pericarditis serves as a cash cow.
פילוחים אנליטיים ודוחות נתונים של חברת Kiniksa (KNSA)
This metric reflects the net cash balance after deducting all operating and financial expenses, demonstrating the actual efficiency of value generation amid shifting liquidity. An analysis of Kiniksa Pharmaceuticals (KNSA) cash profit allows for an assessment of business resilience, where stable revenue growth from the sale of the drug Inertia confirms the high commercial value of the therapy and minimizes the risks of capital drawdown.